# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-15-2024 | 03-31-2024 | 10-Q | |
2 | 03-27-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Jack Allen initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Outperform rating and announces P...
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $6 to $7.
As of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractu...
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...